• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Immuno-oncology summit Europe 2023 (London, June 20-22)

June 15, 2023 By Caroline Lonez

Our lead scientist Jennifer Bolsée will provide an update on our NKG2D-based multi-specific CAR T-cells at the advances in CAR T-cell engineering session on June 22nd.

If you want to know how NKG2D-based dual CAR T-cells could help to overcome antigen escape and improve anti-tumor efficacy, come to attend her presentation!

 

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use